Lilly is seeking approval of the 5-HT1F agonist on the strength of late-phase data showing the drug can clear headache pain in two hours.

Synthorx wants a $100 million IPO, but is the window closing?

The FDA granted a de novo clearance to Atlantic Therapeutics’ electrical muscle stimulator for women, for treating stress urinary incontinence.

Days after poaching a health system executive to pull together its disparate healthcare ventures, Google moved to reabsorb DeepMind’s health business.

Elliot Ehrich, M.D., who capped an 18-year career at Alkermes in January, has joined Expansion Therapeutics as its chief medical officer.

Deerfield Management committed up to $80 million to fund a new center at the Dana-Farber Cancer Institute set on exploring protein degradation.

Mesoblast shares dive after its stem cell therapy fails to wean heart failure patients off left ventricular assist devices in a phase 2 trial.

The financing, which comes 15 months after Roivant raised $1.1 billion, is tied to a $7 billion valuation for the fast-growing biotech.

NextCure will use the series B funds to advance Siglec-15-targeting antibody NC318 and another asset through early-phase clinical development.